Differentiation modulating agents and uses therefor
AssigneeVerva Pharmaceuticals Pty Ltd
InventorsJohannes Bernhard Prins, Louise Joyce Hutley, Ross Peter McGeary
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
Claims17
A method of treating obesity or conditions of localized increases in adipogenesis, comprising administering to a human patient in need of such treatment, an adipogenesis-inhibiting effective amount of an agent that antagonizes expression of a gene encoding an FGF receptor (FGFR) or antagonizes the level or functional activity of an expression product of the FGFR gene.
Dependencies are inferred from the claim text.